ARM Sector Newsletter
The latest news in gene therapy, cell therapy, and tissue engineering
May 28, 2020
Quick Links
Join ARM for Our Next Webinar: Value Based Payments 101
May 28, 2020 – (ARM) – Cell and gene therapies are changing the face of medicine and providing hope to patients with serious diseases and disorders. But how will we pay for these potentially curative treatments? Next Wednesday, June 3, experts from the MIT NEWDIGS Project, Harvard Pilgrim Health Care, AveXis, and the EveryLife Foundation for Rare Diseases will discuss innovative payment models for the next wave of medicine. Register today!
Big Gene Therapy Names Line Up Behind Experimental COVID-19 Vaccine
May 28, 2020 – (STAT News) – An early stage vaccine against COVID-19 based on the same basic technology used in gene therapy is gaining some support from some of that field’s biggest names.
ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing, and Marketing Agreement
May 27, 2020 – (NantKwest) – The binding agreement outlines how development costs will be shared, how profits will be apportioned for any successfully marketed products, and the structure of shared governance of the joint work.
Could Cell Therapy Target Severe COVID-19?
May 25, 2020 – (Labiotech) – Representatives from Athersys and Pluristem Therapeutics provided updates on their clinical programs to treat ARDS caused by COVID-19 on ARM's May 21 webinar. A recording of the webinar is available online.
FibroGenesis Reports Data From Animal Models of COVID-19 Treated With Fibroblast Cell Therapy
May 21, 2020 – (FibroGenesis) – FibroGenesis's PneumoBlast cell therapy showed a 37% improvement in outcome compared to BMSCs. After the introduction of PneumoBlast, average LWW/BW ratios returned to baseline control numbers of healthy lungs.
Cabaletta Bio Announces Expansion of Sponsored Research Agreement With the University of Pennsylvania
May 28, 2020 – (Cabaletta Bio) – The agreement expands the scope of sponsored research to include three additional B cell-mediated autoimmune diseases. Cabaletta Bio also has a license agreement with Penn that provides the company with access to multiple patent families covering CAAR T cell therapy as applied to the field of B cell-mediated autoimmune and alloimmune diseases.
Atara Biotherapeutics Announces Pricing of $175.5M Public Offering
May 27, 2020 – (Atara Biotherapeutics) – Atara Biotherapeutics announced the pricing of an underwritten public offering of 12.6M shares of its common stock. The offering is expected to close on or about May 29.
EdiGene and Immunochina Announce Research and Development Collaboration for Allogeneic CAR-T Therapy for Cancer
May 27, 2020 – (EdiGene) – Under this partnership, both companies will combine EdiGene’s expertise in genome editing and allogeneic T-cell process with Immunochina’s expertise in innovative CAR-T technology to develop potentially best-in-class allogeneic CAR-T therapeutics. Terms were not disclosed.
Iovance Biotherapeutics Announces Proposed Public Offering of Common Stock
May 27, 2020 – (Iovance Biotherapeutics) – Iovance Biotherapeutics announced that it intends to offer and sell $500M of its common stock, and to grant the underwriters an option to purchase up to $75M of additional shares. Iovance intends to use the proceeds from this offering to support the potential commercial launch of lifileucel for advanced melanoma and LN-145 for advanced cervical cancer.
Shanghai Cell Therapy Group Launches Collaboration With USC Researcher to Improve the Ex Vivo Expansion of Hematopoietic Stem Cells for Clinical Applications
May 27, 2020 – (Shanghai Cell Therapy Group) – Through the project, sponsored by $3.6M from the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.
Startup Targets Glioblastoma Tumors With CAR-T Therapy
May 27, 2020 – (McMaster University) – Scientists at McMaster University and the University of Toronto have developed a CAR-T therapy for the aggressive brain cancer glioblastoma. The researchers have launched a startup called Empirica Therapeutics, which aims to bring the CAR-T drug into clinical trials in recurrent glioblastoma patients by 2022.
Caladrius Biosciences Announces $4.3M Registered Direct Offering
May 26, 2020 – (Caladrius Biosciences) – The company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology-based clinical programs.
Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 26, 2020 – (Gamida Cell) – After giving effect to the option closing, the aggregate gross proceeds to the company were approximately $69M before deducting underwriting discounts and commissions and estimated offering expenses.
Novasep and Lysogene Announce Their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product
May 26, 2020 – (Lysogene) – With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene’s lead gene therapy product, LYS-SAF302, currently in Phase 2/3 development.
Prescient Therapeutics Licenses Technologies From University of Pennsylvania and Oxford University to Create Innovative Universal CAR Platform
May 26, 2020 – (Prescient Therapeutics) – Prescient Therapeutics has signed an exclusive global licensing agreement with the University of Pennsylvania for an innovative universal immune receptor technology platform. In addition, Prescient has also obtained a global, non-exclusive license from Oxford University to use the SpyTag/SpyCatcher molecular binding system employed by the platform.
ViaCyte Announces $27M Financing to Advance Next Generation Cell Therapies for Diabetes
May 26, 2020 – (ViaCyte) – Proceeds from the financing will be used to further advance the company's multi-product candidate approach to develop medicines that have the potential to transform the way insulin-requiring diabetes is managed, potentially providing a functional cure for patients with type 1 diabetes.
WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs-NSCLC in Combination with Nivolumab for the Treatment of Non-Small Cell Lung Cancer
May 28, 2020 – (WindMIL) – MILs-NSCLC is an adoptive cell therapy produced via WindMIL’s proprietary process to activate, transform, and expand T cells derived from the bone marrow of patients with NSCLC.
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel From C-144-01 Clinical Study in Advanced Melanoma
May 27, 2020 – (Iovance Therapeutics) – The data from the first 68 patients in Cohort 4 demonstrated a 32.4% overall response rate at 5.3 months of median study follow up. For Cohort 2, median duration of response has not been reached at 18.7 months of follow up.
Passage Bio Receives Rare Pediatric Disease Designation forPBGM01 for Patients with GM1 Gangliosidosis
May 21, 2020 – (Passage Bio) – PBGM01 is an AAV-delivery gene therapy currently being developed for the treatment of infantile GM1 gangliosidosis and has previously been granted Orphan Drug designation. The company plans to initiate a Phase 1/2 trial in the fourth quarter of 2020 with initial safety and biomarker data expected in the late first half of 2021.
Unique Insight Into Development of the Human Brain: Model of the Early Embryonic Brain
May 25, 2020 – (University of Copenhagen) – The new model will allow researchers to make a map of the development of the brain cells, which could be used as a guide to produce different types of nerve cells for stem cell therapy.
Animal Study Shows Human Brain Cells Repair Damage in Multiple Sclerosis
May 19, 2020 – (University of Rochester Medical Center) – Researchers found that when human glia progenitor cells are transplanted into adult mouse models of progressive multiple sclerosis, the cells migrated to where needed in the brain, created new oligodendrocytes, and replaced the lost myelin. The study also showed that this process of remyelination restored motor function in the mice.
Executive Director
ARM Foundation for Cell and Gene Medicine – Remote
About ARM

The Alliance for Regenerative Medicine (ARM) is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide. By leveraging the expertise of its membership, ARM empowers multiple stakeholders to promote legislative, regulatory and public understanding of, and support for, this expanding field. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit
Regenerative Medicine Forum
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine
Subscribe to Newsletter
Become a Member
Event Calendar
Copyright © 2020 AllianceRM, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe.